---
title: "Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281370050.md"
description: "Zhaoke Ophthalmology is seeking approval from China's National Medical Products Administration for three ophthalmic medications, with Chairman Li Xiaoyi optimistic about receiving approval this year. The company plans to increase marketing expenses and personnel allocation, and aims to expand into overseas markets, targeting revenue generation by 2028. Zhaoke anticipates international sales to make up half of its total revenue, focusing on the Latin American market, especially Brazil. Additionally, the company is registering its products in Hong Kong and Macau for broader application in the Greater Bay Area."
datetime: "2026-04-01T12:37:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281370050.md)
  - [en](https://longbridge.com/en/news/281370050.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281370050.md)
---

# Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year

Zhaoke Ophthalmology is currently seeking approval from China's National Medical Products Administration for the commercialization of three ophthalmic medications. According to Ming Pao, Chairman and Executive Director Li Xiaoyi expressed optimism about receiving approval within this year, paving the way for commercialization. Prior to this, Li anticipates a significant increase in marketing and promotional expenses, along with personnel allocation. Li also disclosed plans to expand into overseas markets, with expectations to generate revenue starting in 2028 following overseas registration and approval. The company aims for international sales to eventually constitute half of its total revenue, with a strategic focus on entering the Latin American market, particularly Brazil. Additionally, Zhaoke Ophthalmology has initiated registration processes for its products in Hong Kong and Macau, aiming for broader application within the Greater Bay Area.

### Related Stocks

- [06622.HK](https://longbridge.com/en/quote/06622.HK.md)

## Related News & Research

- [Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM](https://longbridge.com/en/news/286577328.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Lexitas Pharma Services, a Leading Ophthalmology CRO, Announces the Acquisition of Erie Retina Research, CASExERIE and Element Erie](https://longbridge.com/en/news/286907835.md)
- [Kivo Launches Headless GxPTM to Power Compliant Agentic AI in Drug Development](https://longbridge.com/en/news/287071239.md)